[go: up one dir, main page]

PE20191557A1 - Compuestos de pirimidinil-pyridiloxi-naftil y metodos para tratar enfermedades y trastornos relacionados con ire1 - Google Patents

Compuestos de pirimidinil-pyridiloxi-naftil y metodos para tratar enfermedades y trastornos relacionados con ire1

Info

Publication number
PE20191557A1
PE20191557A1 PE2019001893A PE2019001893A PE20191557A1 PE 20191557 A1 PE20191557 A1 PE 20191557A1 PE 2019001893 A PE2019001893 A PE 2019001893A PE 2019001893 A PE2019001893 A PE 2019001893A PE 20191557 A1 PE20191557 A1 PE 20191557A1
Authority
PE
Peru
Prior art keywords
compounds
naftile
pyridyloxy
disorders1
pirimidinyl
Prior art date
Application number
PE2019001893A
Other languages
English (en)
Inventor
Marie-Gabrielle Braun
Paul Gibbons
Wendy Lee
Cuong Ly
Joachim Rudolph
Jacob Schwarz
Avi Ashkenazi
Leo Fu
Tommy Lai
Fei Wang
Ramsay Beveridge
Liang Zhao
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63522807&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20191557(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of PE20191557A1 publication Critical patent/PE20191557A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pyridine Compounds (AREA)

Abstract

REFERIDO A COMPUESTOS PIRIMIDINIL-PIRIDILOXI-NAFTIL DE FORMULA (I') DONDE R1, R2, R3, R4, R5, R6, R7 Y n SON TAL COMO SE DEFINEN EN LA DESCRIPCION. SON COMPUESTOS PREFERIDOS: (S)-3-(2-CIANOPROPAN-2-IL)-N-(6-METIL-5-((3-(2-(PIPERIDIN-3-ILAMINO)PIRIMIDIN-4-IL)PIRIDIN-2-IL)OXI)NAFTALEN-1-IL)BENZAMIDA; (S)-1-(2-CLOROFENIL)-N-(2-FLUORO-6-METIL-5-((3-(2-(PIPERIDIN-3-ILAMINO)PIRIMIDIN-4-IL)PIRIDIN-2-IL)OXI)NAFTALEN-1-IL)METANOSULFONAMIDA; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS TIENEN ACTIVIDAD DE MODULACION DE LA ENZIMA REQUIRENTE DE INOSITOL 1 (IRE1) SIENDO UTILES EN EL TRATAMIENTO DE CANCER MICROCITICO DE PULMON, ADENOCARCINOMA DE PULMON
PE2019001893A 2017-03-17 2018-03-16 Compuestos de pirimidinil-pyridiloxi-naftil y metodos para tratar enfermedades y trastornos relacionados con ire1 PE20191557A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2017077059 2017-03-17
PCT/CN2018/079292 WO2018166528A1 (en) 2017-03-17 2018-03-16 Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders

Publications (1)

Publication Number Publication Date
PE20191557A1 true PE20191557A1 (es) 2019-10-24

Family

ID=63522807

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2019001893A PE20191557A1 (es) 2017-03-17 2018-03-16 Compuestos de pirimidinil-pyridiloxi-naftil y metodos para tratar enfermedades y trastornos relacionados con ire1

Country Status (17)

Country Link
US (1) US10968203B2 (es)
EP (1) EP3596063A4 (es)
JP (1) JP6925435B2 (es)
KR (1) KR20190141145A (es)
CN (1) CN111247136A (es)
AR (1) AR111281A1 (es)
AU (1) AU2018233402A1 (es)
BR (1) BR112019019193A2 (es)
CA (1) CA3056833A1 (es)
CL (1) CL2019002671A1 (es)
CO (1) CO2019010078A2 (es)
CR (1) CR20190433A (es)
IL (1) IL269302A (es)
PE (1) PE20191557A1 (es)
SG (1) SG11201908517XA (es)
TW (1) TW201838981A (es)
WO (1) WO2018166528A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12156523B2 (en) 2017-03-17 2024-12-03 Mmag Co., Ltd. Plant disease control agent
US10392367B2 (en) 2017-06-01 2019-08-27 Quentis Therapeutics, Inc. IRE1 small molecule inhibitors
EP3630748B1 (en) 2017-06-01 2023-04-19 Cornell University Ire1 small molecule inhibitors
WO2020047518A1 (en) * 2018-08-30 2020-03-05 The Regents Of The University Of California Ire1 kinase inhibitors and uses thereof
TWI831829B (zh) 2018-09-12 2024-02-11 美商建南德克公司 苯氧基-吡啶基-嘧啶化合物及使用方法
CN112689528B (zh) * 2018-09-12 2024-05-14 基因泰克公司 嘧啶基-杂芳氧基-萘基化合物和使用方法
JP7546299B2 (ja) * 2018-12-03 2024-09-06 コーネル・ユニバーシティー Ｉｒｅ１小分子阻害物質
WO2020117634A1 (en) * 2018-12-03 2020-06-11 Cornell University Ire1 small molecule inhibitors
CN113508115A (zh) 2019-01-03 2021-10-15 基因泰克公司 吡啶并嘧啶酮和蝶啶酮化合物作为需要酶i(ire i α)的内切核糖核酸酶肌醇的抑制剂用于治疗癌症疾病
US12479818B2 (en) 2019-05-15 2025-11-25 Cornell University Treatment of fibrosis with IRE1 small molecule inhibitors
EP4192462A4 (en) * 2020-08-07 2024-09-04 Optikira LLC PYRAZOLOPYRIDINE COMPOUNDS AND METHODS OF INHIBITING IRE1 USING THEM
WO2022104148A1 (en) * 2020-11-13 2022-05-19 The Regents Of The University Of California Ire1alpha inhibitors and uses thereof
US11884649B2 (en) 2020-11-13 2024-01-30 The Regents Of The University Of California IRE1α inhibitors and uses thereof
CN114907350B (zh) * 2021-02-10 2023-12-29 上海凌达生物医药有限公司 一类含氮稠环类化合物、制备方法和用途
CN116693357B (zh) * 2023-06-07 2026-01-27 西安工程大学 一种β-三氟甲基不饱和酰胺及其合成方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005113494A2 (en) * 2004-05-07 2005-12-01 Amgen Inc. Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer
US7868177B2 (en) 2006-02-24 2011-01-11 Amgen Inc. Multi-cyclic compounds and method of use
JP6144873B2 (ja) 2008-09-15 2017-06-07 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｉｒｅ１、ｓｒｃ、及びａｂｌ活性を調節するための方法及び組成物
ES2638317T3 (es) 2013-04-04 2017-10-19 Janssen Pharmaceutica Nv Nuevos derivados de N-(2,3-dihidro-1H-pirrolo[2,3-b]piridin-5-il)-4-quinazolinamina y N-(2,3-dihidro-1H-indol-5-il)-4-quinazolinamina como inhibidores de PERK

Also Published As

Publication number Publication date
AR111281A1 (es) 2019-06-26
CR20190433A (es) 2019-11-20
SG11201908517XA (en) 2019-10-30
CA3056833A1 (en) 2018-09-20
JP6925435B2 (ja) 2021-08-25
CN111247136A (zh) 2020-06-05
TW201838981A (zh) 2018-11-01
AU2018233402A1 (en) 2019-10-10
IL269302A (en) 2019-11-28
BR112019019193A2 (pt) 2020-04-22
JP2020514377A (ja) 2020-05-21
KR20190141145A (ko) 2019-12-23
CL2019002671A1 (es) 2019-12-06
US10968203B2 (en) 2021-04-06
CO2019010078A2 (es) 2020-01-17
EP3596063A4 (en) 2020-12-30
EP3596063A1 (en) 2020-01-22
US20180265497A1 (en) 2018-09-20
WO2018166528A1 (en) 2018-09-20

Similar Documents

Publication Publication Date Title
PE20191557A1 (es) Compuestos de pirimidinil-pyridiloxi-naftil y metodos para tratar enfermedades y trastornos relacionados con ire1
PE20191541A1 (es) Composiciones y metodos para inhibir la accion de la arginasa
MX2023004923A (es) Compuestos heterociclicos como inmunomoduladores.
PE20200696A1 (es) Moduladores de moleculas pequenas de sting humana
CL2020002146A1 (es) Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer.
PE20151274A1 (es) Inhibidores de erk y sus usos
PE20210642A1 (es) Inhibidores de pd-1/pd-l1
EA202092490A1 (ru) Модуляторы метилмодифицирующих ферментов, композиции и их применения
EA201891203A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
PE20141824A1 (es) Compuestos terapeuticamente activos y sus metodos de uso
PE20161225A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
PE20170705A1 (es) Nuevos compuestos como inhibidores de ret (reorganizado durante la transfeccion)
EA201890641A2 (ru) СТИМУЛЯТОРЫ sGC
PE20160548A1 (es) Sulfonamidas como moduladores de canales de sodio
EA201890594A1 (ru) Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний
PE20230180A1 (es) Uso de bi853520 en tratamiento contra el cancer
PE20141855A1 (es) Benzotienilo-pirrolotriazinas disustituidas y sus usos
CY1126039T1 (el) Ενωσεις και συνθεσεις ουριας ως αναστολεις της ατρ-ασης smarca2/brm
PE20140626A1 (es) Compuestos de bis(fluoroalquil)-1,4-benzodiazepinona
AR085195A1 (es) Metodo de tratamiento de cancer
BR112015006828A2 (pt) composto, ou um sal farmaceuticamente aceitável do mesmo; composição farmacêutica; método para tratar uma doença em um paciente em necessidade do tratamento; e método para modular a atividade de uma proteína ire1
PE20170004A1 (es) Inhibidores de biaril cinasa
MX2018010191A (es) Inhibidores de glucosidasa.
EA201790142A1 (ru) Лечение лейкоза ингибиторами гистондеацетилазы
PL417066A1 (pl) Inhibitory arginazy oraz ich zastosowania terapeutyczne